Article Data

  • Views 3392
  • Dowloads 180

Original Research

Open Access

DEPRESSION AUGMENTS THE PRODUCTION OF HIGH-AFFINITY ANTIBODIES AGAINST ESTROGEN METABOLITE-RECEPTOR COMPLEX IN PROSTATE CANCER PATIENTS

  • Wahid Ali Khan1
  • Mohd. Wajid Ali Khan2

1Department of Clinical Biochemistry, College of Medicine, King Khalid University, Abha, Saudi Arabia

2Department of Chemistry, College of Science, University of Hail, Hail-2440, Saudi Arabia.

DOI: 10.31083/jomh.v16i4.268 Vol.16,Issue 4,October 2020 pp.72-83

Published: 01 October 2020

*Corresponding Author(s): Wahid Ali Khan E-mail: wahidalikhan@rediffmail.com

Abstract

Background

Depression is a common symptom associated with prostate cancer (PC), elevated levels of 16α-hydroxye-strone (16α-OHE1) have been linked to increased risk of PC and estrogen receptor (ER) had been expressed in prostate tissue. This study was carried out to know whether depression augments the production of anti-bodies against 16α-OHE1-ER in PC patients.

Methods

Forty-six depressed PC (DPC) (out of total 60 PC) patients and 40 control subjects (who have normal circu-lating prostate-specific antigen [PSA] levels) were checked for the presence of antibodies by ELISA (direct binding and competition) and quantitative precipitin titration.

Results

Antibodies from DPC patients demonstrate high binding to 16α-OHE1-ER in comparison to overall PC patients (p<0.05) and controls (p<0.001). Although, PC sera showed high binding to 16α-OHE1-ER in com-parison to ER (p<0.05) or 16α-OHE1 (p<0.001). The relative affinity of IgGsfrom DPC and PC patients was 1.01×10−7 and 1.19×10−7 M, respectively.

Conclusions

Depression triggers high-affinity antibodies against this antigen in PC patients through inflammatory con-ditions. It also increased the release of pro-inflammatory cytokine (IL-6) that further enhanced antibodies in PC patients.

Keywords

16α-hydroxyestrone; antibodies; depression; estrogen receptor; prostate cancer

Cite and Share

Wahid Ali Khan,Mohd. Wajid Ali Khan. DEPRESSION AUGMENTS THE PRODUCTION OF HIGH-AFFINITY ANTIBODIES AGAINST ESTROGEN METABOLITE-RECEPTOR COMPLEX IN PROSTATE CANCER PATIENTS. Journal of Men's Health. 2020. 16(4);72-83.

References

1. Feruaha G, Izad JP, Tripp DA, Rajan S, Leong DP, Siemens DR. Depression and prostate cancer: A focused review for clinician. Urol Oncol. 2019;17: 282–8. https://doi.org/10.1016/j.urolonc.2018.12.020

2. Cheng Y, Tang XY, Li YX, Zhao DD, Cao QH, Wu HX, et al. Depression-induced neuropep-tide Y secretion promotes prostate cancer growth by recruiting myeloid cells. Clin Cancer Res. 2019;25(8):2633–43. https://doi.org/10.1158/1078-0432.CCR-18-2912

3. Sanda MG, Ayyagari SR, Jaffeer EM, Epstein JI, Clift SL, Cohen LK, et al. Demonstration of a ratio-nal strategy for human prostate cancer gene ther-apy. J Urol. 1994;151:622–8. https://doi.org/10.1016/S0022-5347(17)35032-2

4. Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, et al. Autoantibody signatures in prostate cancer. N Engl J Med. 2005;353:1224–35. https://doi.org/10.1056/NEJMoa051931

5. Snaterse G, Visser JA, Arlt W, Hofland J. Circulating steroid hormone variations throughout different stages of prostate cancer. Endocr Relat Cancer. 2017;24: R403–20. https://doi.org/10.1530/ERC-17-0155

6. Teas J, Cumningham JE, Fowke JH, Nitcheva D, Kanwat CP, Boulware RJ, et al. Urinary estrogen metabolites, prostate specific antigen, and body mass index among African-American men in South Carolina. Cancer Detect Prev. 2005;29:494–500. https://doi.org/10.1016/j.cdp.2005.08.004

7. Muti P, Westerlind K, Wu T, Grimaldi T, Berry JD, Schunemann H, et al. Urinary estrogen metabolites and prostate cancer: A case-control study in United States. Cancer Causes Control. 2002;13:947–55. https://doi.org/10.1023/A:1021986811425

8. Kosti O, Xu X, Veenstra TD, Hsing AW, Chu LW, Goldman K, et al. Urinary estrogen metabolites and prostate cancer risk: A pilot study. Prostate. 2011;71(5):507–16. https://doi.org/10.1002/pros.21262

9. Khan WA, Alam K, Moinuddin. Catechol-estrogen modified DNA: A better antigen for cancer anti-body. Arch Biochem Biophys. 2007;465:293–300. https://doi.org/10.1016/j.abb.2007.06.006

10. Khan WA, Khan MWA, Sherwani S, Siddiqui WA. Depression enhanced the production of autoanti-bodies against 16α-hydroxyestrone-estrogen recep-tor adduct in breast cancer. Int Immunopharmacol. 2019;66:251–9. https://doi.org/10.1016/j.intimp.2018. 11.018

11. Khan WA, Zaman GS. Detection of 16α-hydroxye-strone-histone 1 adduct as high-affinity antigen for rheumatoid arthritis autoantibodies. Arch Immunol Ther Exp. 2018;66:379–88. https://doi.org/10.1007/s00005-018-0512-z

12. Khan WA, Habib S, Khan MWA, Alam K, Moinuddin. Enhanced binding of circulating SLE autoantibodies to catecholestrogen-copper- modified DNA. Mol Cell Biochem.2008;315:143–50. https://doi.org/10.1007/s11010-008-9798-1

13. Khan WA, Moinuddin. Binding characteristics of SLE Anti-DNA autoantibodies to catechol-estrogen modified DNA. Scand J Immunol. 2006;64:667–83. https://doi.org/10.1111/j.1365-3083.2006.01855.x

14. de Ronde W, Pois HA, van Leeuwen JP, de Jong FH. The importance of oestrogen in males. Clin Endocrinol (Oxf). 2003;58:529–42. https://doi. org/10.1046/j.1365-2265.2003.01669.x

15. Taplin ME, Ho SM. Clinical review 134: The endo-crinology of prostate cancer. J Clin Endocrinol Metab. 2001;58:3467–77. https://doi.org/10.1210/jcem.86.8.7782

16. Rice SM, Oliffe JL, Kelly MT, et al. Depression and prostate cancer: Examining comorbidity and male-specific symptoms. Am J Mens Health. 2018;12(6):1864–72. https://doi.org/10.1177/1557988 318784395

17. Goding JW. Use of staphylococcal protein–A as immunological reagent. J Immunol Methods. 1978;20: 241–54. https://doi.org/10.1016/0022-1759(78)90259-4

18. Bradford MM. A rapid and sensitive method for quantitation of micrograms quantity of pro-tein utilizing the principle of protein dye bind-ing. Anal Biochem. 1976;72:248–54. https://doi. org/10.1016/0003-2697(76)90527-3

19. Langumir I. The adsorption of gas on plane sur-face glass, mica and platinum. J Am Chem Soc. 1918;40:1361–403. https://doi.org/10.1021/ja02242a004

20. Nelles JL, Hu WY, Prins GS. Estrogen action and prostate cancer. Expert Rev Endocrinol Metab. 2011;6(3):437–51. https://doi.org/10.1586/eem.11.20

21. Bosland MC. The role of estrogens in prostate car-cinogenesis: A rationale for chemoprevention. Rev Urol. 2005;7(3):S4–10.

22. Spiegel D, Giese-Davis J. Depression and can-cer: Mechanisms and disease progression. Biol Psychiatry. 2003;54:269–82. https://doi.org/10.1016/S0006-3223(03)00566-3

23. Saini A, Berruti A, Crucco C, Sguazzotti E, Propiglia F, Russo L, et al. Psychological dis-tress in men with prostate cancer receiving adju-vant androgen- deprivation therapy. Uro Oncol. 2013;31(3):352–8. https://doi.org/10.1016/j.urolonc. 2011.02.005

24. Sharp L, O’Leary F, Kinnear H, Gavin A, Drummond FJ. Cancer related symptoms predict psychological well being among prostate cancer survivors: Results from PiCTure study. Psycho Oncol. 2016;25(3): 282–91. https://doi.org/10.1002/pon.3909

25. Nakashima J, Tachibama M, Horiguchi Y, Oye M, Ohigashi T, Asakura M, et al. Serum interleukin 6 as a prognostic factor in patients with prostate can-cer. Clin Cancer Res. 2000;6:2702–6.

26. Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate can-cer. Am J Pathol. 2001;159:2159–65. https://doi. org/10.1016/S0002-9440(10)63067-2

27. Pavan B, Paqanetto G, Biondi C, Lunghi L. Estrogen metabolites in the release of inflammatory mediators from human amnion-derived cells. Life Sci. 2011;88(11–12):551–8. https://doi.org/10.1016/j. lfs.2011.01.018

28. Plaskon LA, Penson DF, Vaughan TL, Stanford JL. Cigarette smoking and risk of prostate cancer in middle-age men. Cancer Epidemiol Biomarkers Prev. 2003;12:604–9.

29. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: Review and perspec-tives. Carcinogenesis. 1998;19:1–27. https://doi. org/10.1093/carcin/19.1.1

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Directory of Open Access Journals (DOAJ) DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.

SCImago The SCImago Journal & Country Rank is a publicly available portal that includes the journals and country scientific indicators developed from the information contained in the Scopus® database (Elsevier B.V.)

Publication Forum - JUFO (Federation of Finnish Learned Societies) Publication Forum is a classification of publication channels created by the Finnish scientific community to support the quality assessment of academic research.

Scopus: CiteScore 0.7 (2022) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Norwegian Register for Scientific Journals, Series and Publishers Search for publication channels (journals, series and publishers) in the Norwegian Register for Scientific Journals, Series and Publishers to see if they are considered as scientific. (https://kanalregister.hkdir.no/publiseringskanaler/Forside).

Submission Turnaround Time

Conferences

Top